CD19+ relapse/refractory B-ALL

Clinical trials for CD19+ relapse/refractory B-ALL explained in plain language.

Never miss a new study

Get alerted when new CD19+ relapse/refractory B-ALL trials appear

Sign up with your email to follow new studies for CD19+ relapse/refractory B-ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1

Experimental shot at stubborn blood cancers: LV009 injection enters early human trial

Disease control Not yet recruiting

This early-phase trial will test the safety of an experimental cell therapy called LV009 injection in 19 adults with relapsed or refractory CD19-positive blood cancers. Participants receive a single infusion, then are monitored for side effects and tumor response for up to 24 mon…

Matched conditions: CD19+ RELAPSE/REFRACTORY B-ALL

Early phase 1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control

Last updated Jun 27, 2026 08:09 UTC

CD19+ relapse/refractory B-ALL

Get alerted when new CD19+ relapse/refractory B-ALL trials appear

Experimental shot at stubborn blood cancers: LV009 injection enters early human trial